• PDR Search

    Required field
  • Advertisement
  • Dilantin


    Dilantin Infatabs, Dilantin-125







    Tonic-Clonic (Grand Mal) and Psychomotor (Temporal Lobe) Seizure:
    125mg (1 tsp) tid
    May increase to 625mg (5 tsp) daily

    Generalized Tonic-Clonic (Grand Mal) and Complex Partial (Psychomotor/Temporal Lobe) Seizures and Prevention/Treatment of Neurosurgery-Associated Seizures:
    Cap, ER:

    Divided Daily Dosing:
    Initial: 100mg tid
    Maint: 100mg tid-qid
    Titrate: May increase up to 200mg tid, if necessary

    QD Dosing:
    May consider 300mg qd if seizure is controlled on divided doses of three 100mg caps daily
    LD (Clinic/Hospital):
    Initial: 1g in 3 divided doses (400mg, 300mg, 300mg) at 2-hr intervals
    Maint: Start maint dose 24 hrs after LD
    Do not give oral loading regimen in patients w/ history of renal/liver disease

    Tab, Chewable:
    Initial: 100mg (2 tabs) tid
    Maint: 300-400mg (6-8 tabs) daily
    Titrate: May increase to 600mg (12 tabs) daily

    Do not change dose at intervals <7-10 days



    Tonic-Clonic (Grand Mal) or Psychomotor (Temporal Lobe) Seizure:
    Initial: 5mg/kg/day in 2 or 3 equally divided doses
    Maint: 4-8mg/kg/day
    Max: 300mg/day

    Generalized Tonic-Clonic (Grand Mal) and Complex Partial (Psychomotor/Temporal Lobe) Seizures and Prevention/Treatment of Neurosurgery-Associated Seizures:
    Cap, ER/Tab, Chewable:

    Initial: 5mg/kg/day in 2 or 3 equally divided doses
    Maint: 4-8mg/kg/day
    Max: 300mg/day

    >6 Years: May require the minimum adult dose (300mg/day)

    Do not change dose at intervals <7-10 days


    May require lower or less frequent dosing

    Other Important Considerations
    May require dose adjustment when switching from product formulated w/ free acid to product formulated w/ Na+ salt and vice versa


    Oral route

    Tab, Chewable
    May chew or swallow tab whole
    Not for once-a-day dosing
    If daily dose cannot be divided equally, give larger dose hs

    Use an accurately calibrated measuring device to ensure accurate dosing


    Cap, ER: 30mg, 100mg; (Dilantin-125) Sus: 125mg/5mL [237mL]; (Infatabs) Tab, Chewable: 50mg* *scored


    Coadministration with delavirdine.


    Caution in the interpretation of total phenytoin plasma concentrations with renal/hepatic disease, or in those with hypoalbuminemia. Avoid abrupt withdrawal; may precipitate status epilepticus. May increase risk of suicidal thoughts/behavior; monitor for emergence/worsening of depression, suicidal thoughts/behavior, and/or any unusual changes in mood/behavior. Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), reported; d/c at 1st sign of rash, unless the rash is clearly not drug-related. Do not resume therapy, and consider alternative therapy if signs/symptoms suggest SJS/TEN. Avoid use as an alternative for carbamazepine in patients positive for HLA-B*1502. Drug reaction with eosinophilia and systemic symptoms (DRESS)/multiorgan hypersensitivity reported; evaluate immediately if signs and symptoms (eg, rash, fever, lymphadenopathy) are present and d/c if an alternative etiology cannot be established. Caution with history of hypersensitivity to structurally similar drugs (eg, carboxamides, barbiturates, succinimides, oxazolidinediones); consider alternatives to therapy. Acute hepatotoxicity (eg, acute hepatic failure) reported; d/c immediately and do not readminister. Hematopoietic complications and lymphadenopathy reported; extended follow-up observation is indicated and every effort should be made to achieve seizure control using alternative antiepileptic drugs in all cases of lymphadenopathy. Decreased bone mineral density and bone fractures reported during chronic use; consider screening and initiating treatment plans as appropriate. Caution with porphyria, hepatic impairment, and in elderly or gravely ill patients. Bleeding disorder in newborns may occur; give vitamin K to mother before delivery and to neonate after birth. Check plasma levels immediately if early signs of dose-related CNS toxicity develop. Hyperglycemia reported; may increase serum glucose levels in diabetics. Not indicated for seizures due to hypoglycemia or other metabolic causes. Not effective for absence (petit mal) seizures; if tonic-clonic (grand mal) and absence (petit mal) seizures are present, combined drug therapy is needed. May produce confusional states at levels sustained above optimal range; reduce dose if plasma levels are excessive, or d/c if symptoms persist. Lab test interactions may occur. (Cap, ER) Do not use if discolored. (Tab, Chewable) Not for qd dosing.


    Rash, nystagmus, ataxia, slurred speech, decreased coordination, somnolence, mental confusion, dizziness, insomnia, transient nervousness, motor twitching, N/V, thrombocytopenia, altered taste sensation, Peyronie's disease.


    See Contraindications. Acute alcohol intake, amiodarone, antiepileptic agents (eg, ethosuximide, felbamate, oxcarbazepine, topiramate), azoles (eg, fluconazole, ketoconazole, itraconazole), capecitabine, chloramphenicol, chlordiazepoxide, disulfiram, estrogens, fluorouracil, fluoxetine, fluvastatin, fluvoxamine, H2-antagonists (eg, cimetidine), halothane, isoniazid, methylphenidate, omeprazole, phenothiazines, salicylates, sertraline, succinimides, sulfonamides (eg, sulfamethizole, sulfadiazine, sulfamethoxazole-trimethoprim), ticlopidine, tolbutamide, trazodone, and warfarin may increase levels. Anticancer drugs (eg, bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate), carbamazepine, chronic alcohol abuse, diazepam, diazoxide, folic acid, fosamprenavir, nelfinavir, reserpine, rifampin, ritonavir (RTV), St. John's wort, sucralfate, vigabatrin, and theophylline may decrease levels. Administration with preparations that increase gastric pH (eg, supplements or antacids containing calcium carbonate, aluminum hydroxide, and magnesium hydroxide) may affect absorption; do not take at the same time of day. Phenobarbital, sodium valproate, and valproic acid may increase or decrease levels. May impair efficacy of azoles (eg, fluconazole, ketoconazole, voriconazole), corticosteroids, doxycycline, estrogens, furosemide, irinotecan, oral contraceptives, paclitaxel, paroxetine, quinidine, rifampin, sertraline, teniposide, theophylline, and vitamin D. Increased and decreased PT/INR responses reported with warfarin. May decrease levels of active metabolites of albendazole, certain HIV antivirals (eg, efavirenz, lopinavir/RTV, indinavir), anti-epileptic agents (eg, felbamate, topiramate, quetiapine), atorvastatin, chlorpropamide, clozapine, cyclosporine, digoxin, fluvastatin, folic acid, methadone, mexiletine, nifedipine, nimodipine, nisoldipine, praziquantel, simvastatin, and verapamil. May decrease levels of amprenavir (active metabolite) when given with fosamprenavir alone. May increase levels of amprenavir when given with the combination of fosamprenavir and RTV. Resistance to the neuromuscular blocking action of pancuronium, vecuronium, rocuronium, and cisatracurium reported in patients chronically administered phenytoin; monitor closely for more rapid recovery from neuromuscular blockade than expected and for higher infusion rate requirements. Avoid with enteral feeding preparations and/or nutritional supplements.


    Category D, not for use in nursing.


    Hydantoin; inhibits seizure activity by promoting Na+ efflux from neurons, stabilizing the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane Na+ gradient. Reduces the maximal activity of the brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures.


    Absorption: Tmax=1.5-3 hrs (tab, chewable/sus), 4-12 hrs (cap, ER). Distribution: Plasma protein binding (high); found in breast milk. Metabolism: Liver (hydroxylation). Elimination: Bile (mostly as inactive metabolites), urine; T1/2=22 hrs, 14 hrs (tab, chewable).


    Assess for hypersensitivity to the drug, its inactive ingredients, or other hydantoins, alcohol use, hepatic/renal impairment, porphyria, grave illness, seizures due to hypoglycemia or other metabolic causes, absence seizures, any other conditions where treatment is contraindicated or cautioned, pregnancy/nursing status, and possible drug interactions.


    Monitor for hypersensitivity reactions, dermatologic reactions, DRESS/multiorgan hypersensitivity, hepatotoxicity, hematopoietic complications, lymphadenopathy, decreased bone mineral density, bone fractures, exacerbation of porphyria, hyperglycemia, and other adverse reactions. Monitor for emergence/worsening of depression, suicidal thoughts/behavior, and/or any unusual changes in mood/behavior. Monitor serum levels when switching from Na+ salt to free acid form and vice versa.


    Instruct to read medication guide and to take ud. Advise of the importance of adhering strictly to the prescribed dosage regimen, and of informing the physician of any clinical condition in which it is not possible to take the drug orally as prescribed (eg, surgery). Counsel about the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic reactions; instruct to immediately contact physician if these develop. Caution on the use of other drugs or alcoholic beverages without first seeking physician's advice. Stress the importance of good dental hygiene to minimize the development of gingival hyperplasia and its complications. Advise to notify physician immediately if depression, suicidal thoughts/behavior, or thoughts about self-harm emerge. Encourage patients to enroll in the North American Antiepileptic Drug Pregnancy Registry.


    20-25°C (68-77°F). Protect from moisture. (Cap, ER) Preserve in tight, light-resistant containers. (Sus) Protect from freezing and light.